Wai Wilson Cheung

Dr. Wai Wilson Cheung

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RMRobert H. K. Mak
Robert H. K. Mak
SGSujana Gunta
Sujana Gunta
EOEduardo Oliveira
Eduardo Oliveira
Wai Wilson CheungWai Wilson Cheung
Wai Wilson Cheung
Cachexia associated with chronic kidney disease (CKD) has been linked to GH resistance. In CKD, GH treatment enhances muscular performance. We investigated the impact of GH on cachexia brought on by CKD. CKD was induced by 5/6 nephrectomy in c57BL/6J mice. After receiving GH (10 mg/kg/day) or saline treatment for six weeks, CKD mice were compared to sham-operated controls. GH normalized metabolic rate, increased food intake and weight growth, and improved in vivo muscular function (rotarod and grip strength) in CKD mice. GH decreased uncoupling proteins (UCP)s and increased muscle and adipose tissue ATP content in CKD mice. GH decreased lipolysis of adipose tissue by attenuating expression and protein content of adipose triglyceride lipase and protein content of phosphorylated hormone-sensitive lipase in CKD mice. GH reversed the increased expression of beige adipocyte markers (UCP-1, CD137, Tmem26, Tbx1, Prdm16, Pgc1α, and Cidea) and molecules implicated in adipose tissue browning (Cox2/Pgf2α, Tlr2, Myd88, and Traf6) in CKD mice. Additionally, GH normalized the molecular markers of processes connected to muscle wasting in CKD, such as myogenesis and muscle regeneration. By using RNAseq, we previously determined the top 12 skeletal muscle genes differentially expressed between mice with CKD and control animals. These 12 genes’ aberrant expression has been linked to increased muscle thermogenesis, fibrosis, and poor muscle and neuron regeneration. In this study, we demonstrated that GH restored 7 of the top 12 differentially elevated muscle genes in CKD mice. In conclusion, GH might be an effective treatment for muscular atrophy and browning of adipose tissue in CKD-related cachexia.

31 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
AGAlex Gonzalez
Alex Gonzalez
Wai Wilson CheungWai Wilson Cheung
Wai Wilson Cheung
EPElliot A. Perens
Elliot A. Perens
EOEduardo Oliveira
Eduardo Oliveira
AGArieh Gertler
Arieh Gertler
RMRobert H. K. Mak
Robert H. K. Mak
Mice lacking the functional cystinosin gene (Ctns−/−), a model of infantile nephropathic cystinosis (INC), exhibit the cachexia phenotype with adipose tissue browning and muscle wasting. Elevated leptin signaling is an important cause of chronic kidney disease-associated cachexia. The pegylated leptin receptor antagonist (PLA) binds to but does not activate the leptin receptor. We tested the efficacy of this PLA in Ctns−/− mice. We treated 12-month-old Ctns−/− mice and control mice with PLA (7 mg/kg/day, IP) or saline as a vehicle for 28 days. PLA normalized food intake and weight gain, increased fat and lean mass, decreased metabolic rate and improved muscle function. It also attenuated perturbations of energy homeostasis in adipose tissue and muscle in Ctns−/− mice. PLA attenuated adipose tissue browning in Ctns−/− mice. PLA increased gastrocnemius weight and fiber size as well as attenuated muscle fat infiltration in Ctns−/− mice. This was accompanied by correcting the increased expression of muscle wasting signaling while promoting the decreased expression of myogenesis in gastrocnemius of Ctns−/− mice. PLA attenuated aberrant expressed muscle genes that have been associated with muscle atrophy, increased energy expenditure and lipolysis in Ctns−/− mice. Leptin antagonism may represent a viable therapeutic strategy for adipose tissue browning and muscle wasting in INC.

18 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
ASAna Cristina Simões e Silva
Ana Cristina Simões e Silva
EOEduardo Oliveira
Eduardo Oliveira
Wai Wilson CheungWai Wilson Cheung
Wai Wilson Cheung
RMRobert H. K. Mak
Robert H. K. Mak
Redox signaling alterations contribute to chronic kidney disease (CKD)-associated cachexia. This review aims to summarize studies about redox pathophysiology in CKD-associated cachexia and muscle wasting and to discuss potential therapeutic approaches based on antioxidant and anti-inflammatory molecules to restore redox homeostasis. Enzymatic and non-enzymatic systems of antioxidant molecules have been studied in experimental models of kidney diseases and patients with CKD. Oxidative stress is increased by several factors present in CKD, including uremic toxins, inflammation, and metabolic and hormone alterations, leading to muscle wasting. Rehabilitative nutritional and physical exercises have shown beneficial effects for CKD-associated cachexia. Anti-inflammatory molecules have also been tested in experimental models of CKD. The importance of oxidative stress has been shown by experimental studies in which antioxidant therapies ameliorated CKD and its associated complications in the 5/6 nephrectomy model. Treatment of CKD-associated cachexia is a challenge and further studies are necessary to investigate potential therapies involving antioxidant therapy.

1 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
RMRobert H. K. Mak
Robert H. K. Mak
UQUwe Querfeld
Uwe Querfeld
AGAlex Gonzalez
Alex Gonzalez
SGSujana Gunta
Sujana Gunta
Wai Wilson CheungWai Wilson Cheung
Wai Wilson Cheung
Patients with chronic kidney disease (CKD) often have low serum concentrations of 25(OH)D3 and 1,25(OH)2D3. We investigated the differential effects of 25(OH)D3 versus 1,25(OH)2D3 repletion in mice with surgically induced CKD. Intraperitoneal supplementation of 25(OH)D3 (75 μg/kg/day) or 1,25(OH)2D3 (60 ng/kg/day) for 6 weeks normalized serum 25(OH)D3 or 1,25(OH)2D3 concentrations in CKD mice, respectively. Repletion of 25(OH)D3 normalized appetite, significantly improved weight gain, increased fat and lean mass content and in vivo muscle function, as well as attenuated elevated resting metabolic rate relative to repletion of 1,25(OH)2D3 in CKD mice. Repletion of 25(OH)D3 in CKD mice attenuated adipose tissue browning as well as ameliorated perturbations of energy homeostasis in adipose tissue and skeletal muscle, whereas repletion of 1,25(OH)2D3 did not. Significant improvement of muscle fiber size and normalization of fat infiltration of gastrocnemius was apparent with repletion of 25(OH)D3 but not with 1,25(OH)2D3 in CKD mice. This was accompanied by attenuation of the aberrant gene expression of muscle mass regulatory signaling, molecular pathways related to muscle fibrosis as well as muscle expression profile associated with skeletal muscle wasting in CKD mice. Our findings provide evidence that repletion of 25(OH)D3 exerts metabolic advantages over repletion of 1,25(OH)2D3 by attenuating adipose tissue browning and muscle wasting in CKD mice.

17 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
PZPing Zhou
Ping Zhou
Wai Wilson CheungWai Wilson Cheung
Wai Wilson Cheung
AGAlex Gonzalez
Alex Gonzalez
VVVenya Vaddi
Venya Vaddi
EOEduardo Oliveira
Eduardo Oliveira
RMRobert H. K. Mak
Robert H. K. Mak
Manifestations of infantile nephropathic cystinosis (INC) often include cachexia and deficiency of circulating vitamin D metabolites. We examined the impact of 25(OH)D3 versus 1,25(OH)2D3 repletion in Ctns null mice, a mouse model of INC. Six weeks of intraperitoneal administration of 25(OH)D3 (75 μg/kg/day) or 1,25(OH)2D3 (60 ng/kg/day) resulted in Ctns−/− mice corrected low circulating 25(OH)D3 or 1,25(OH)2D3 concentrations. While 25(OH)D3 administration in Ctns−/− mice normalized several metabolic parameters characteristic of cachexia as well as muscle function in vivo, 1,25(OH)2D3 did not. Administration of 25(OH)D3 in Ctns−/− mice increased muscle fiber size and decreased fat infiltration of skeletal muscle, which was accompanied by a reduction of abnormal muscle signaling pathways. 1,25(OH)2D3 administration was not as effective. In conclusion, 25(OH)D3 supplementation exerts metabolic advantages over 1,25(OH)2D3 supplementation by amelioration of muscle atrophy and fat browning in Ctns−/− mice.

27 March 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
TLTatiana Lobry
Tatiana Lobry
RMRoy Miller
Roy Miller
NNNathalie Nevo
Nathalie Nevo
CRCeline J. Rocca
Celine J. Rocca
JZJinzhong Zhang
Jinzhong Zhang
SCStephanie Cherqui
Stephanie Cherqui
Inflammation is implicated in the pathogenesis of many disorders. Here, we show that cystinosin, protein defective in the lysosomal storage disorder cystinosis, is a critical regulator of galectin-3 during inflammation. Cystinosis is a lysosomal storage disorder and despite ubiquitous expression of cystinosin, kidney is the primary organ to be impacted by the disease. Here, we show that cystinosin interacts with galectin-3 and enhances its lysosomal localization and degradation. Galectin-3 is also found overexpressed in the kidney of the mouse model of cystinosis, Ctns -/- mice. Absence of galectin-3 in Ctns -/- mice led to a better renal function and structure, and decreased macrophage/monocyte infiltration in the kidney. Finally, galectin-3 interacts with a protein implicated in the recruitment of monocytes and macrophages during inflammation, Monocyte Chemoattractant Protein-1 (MCP1), that was found increased in the serum of Ctns -/- mice. These findings highlight a new role of cystinosin and galectin-3 interaction in inflammation, providing a mechanistic explanation for kidney disease pathogenesis in cystinosis, which may lead to the identification of new drug targets to delay its progression.